Nyxoah SA
NYXH
View Detailed Chart
4.650USD
+0.060+1.31%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
174.58MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.31%
5 Days
-2.11%
1 Month
-3.73%
6 Months
-35.86%
Year to Date
+1.09%
1 Year
-57.06%
View Detailed Chart
TradingKey Stock Score of Nyxoah SA
Currency: USD Updated: 2026-02-06Key Insights
Nyxoah SA's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 99 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 11.80.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Nyxoah SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Nyxoah SA Highlights
StrengthsRisks
Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 46.64% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.17M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.17M.
Overvalued
The company’s latest PE is -2.43, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 9.57M shares, increasing 0.71% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.28.
Analyst Rating
Based on
5
analysts
Strong Buy
Current Rating
11.800
Target Price
+157.08%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Nyxoah SA News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Nyxoah SA Info
Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
Ticker SymbolNYXH
CompanyNyxoah SA
CEOTaelman (Olivier)
Websitehttps://www.nyxoah.com/
Related Instruments
+3.02%
+0.09%
+1.60%
+2.48%
+0.40%
-1.14%
-0.05%
-2.35%
-1.76%
+2.65%
+2.64%
+2.03%
+2.01%
+2.38%
+1.70%
+0.16%
+0.78%
+1.72%
+0.59%
-2.02%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
70015.960
+45.830 (+0.07%)
282.580
+22.390 (+8.61%)
2078.470
+26.740 (+1.30%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
